Drugs / CLR 125
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07311993 | Dec 2025 → Feb 2028 expected | breast cancer | Cellectar Biosciences, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-06-24 | Cellectar Biosciences, Inc. | Regulatory Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC) cellectar.com ↗
today announced that the company has submitted a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 1b Dose Finding study of its Auger emitting radiopharmaceutical, CLR 125, for the treatment of relapsed TNBC. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-14 | Cellectar Biosciences, Inc. | Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) cellectar.com ↗ |
| 2025-06-24 | Cellectar Biosciences, Inc. | Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC) cellectar.com ↗ |
| 2017-10-17 | Cellectar Biosciences, Inc. | Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors cellectar.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLR 125 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07311993 ↗ |
| Route | Intravenous | “intended for IV administration” NCT07311993 ↗ |